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Aims Prolonged endothelin (ET) receptor signalling causes vasoconstriction and can lead to hypertension, vascular smooth
muscle hypertrophy, and hyperplasia. Usually, G protein-coupled receptor signalling is negatively regulated by G
protein-coupled receptor kinases (GRKs), preventing prolonged or inappropriate signalling. This study investigated




ET-1-stimulated phospholipase C (PLC) activity and changes in [Ca
2þ]i were assessed using confocal microscopy in
rat MSMCs transfected with the pleckstrin-homology domain of PLCd1 (eGFP-PH) and loaded with Fura-Red. ET-1
applications (30 s) stimulated transient concentration-dependent eGFP-PH translocations from plasma membrane to
cytoplasm and graded [Ca
2þ]i increases. ET-1-mediated PLC signalling was blocked by the type A endothelin
receptor (ETAR) antagonist, BQ123. To characterize ETAR desensitization, cells were stimulated with a maximally
effective concentration of ET-1 (50 nM, 30 s) followed by a variable washout period and a second identical application
of ET-1. This brief exposure to ET-1 markedly decreased ETAR responsiveness to re-challenge, and reversal was
incomplete even after increasing the time period between agonist challenges to 60 min. To assess GRK involvement





D110A,K220RGRK2 expression signiﬁcantly attenuated ETAR
desensitization, whereas other constructs were ineffective. Small interfering RNA-targeted GRK2 depletion equally
attenuated ETAR desensitization. Finally, immunocyotchemical data showed that ETAR activation recruited endogen-
ous GRK2 from cytoplasm to membrane.
Conclusion These studies identify GRK2 as a key regulator of ETAR responsiveness in resistance arteries, highlighting the potential
importance of this GRK isoenzyme in regulating vasoconstrictor signalling pathways implicated in vascular disease.
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Endothelin (ET)-1 is a potent vasoconstrictor controlling vascular
tone with an established role in vascular smooth muscle hyper-
trophy
1,2 and hyperplasia,
3,4 ﬁbrosis and inﬂammatory responses,
leading to vascular remodelling and hypertension.
4,5 ET-1 plays a
crucial role in a number of experimental models of hyperten-
sion,
5,6 and increased plasma ET-1 levels have been reported
in hypertensive patients.
7 Endothelins can signal through two
receptor subtypes ETA and ETB, however in arterial smooth
muscle ETA receptors (ETAR) mediate constrictor responses.
8
ETARs couple through Gaq/11 to activate phospholipase C
(PLC), generating inositol 1,4,5-trisphosphate (IP3) and diacylgly-
cerol (DAG), and leading to the release of intracellular Ca
2þ
stores and the activation of protein kinase C.
2,8 ETAR-mediated
intracellular Ca
2þ increases underlie a major component of
ET-1-induced vasoconstriction. ET-1 also promotes PKC-induced
inhibition of voltage-gated K
þ channels to further enhance
vasoconstriction.
9
Previous studies have shown that antagonizing ETAR signalling
can reverse hypertrophy and hypertension in animal models,
10
indicating a potentially important role for ETAR over-activation
in the development of vascular disease. Over-stimulation of
ETAR signalling clearly has adverse effects on vascular smooth
muscle cells, and understanding the mechanisms that regulate
Gaq/11 signalling is of potential importance in understanding
and treating vascular diseases. Continual or repeated stimulation
of receptors by agonists usually leads to reduced responsiveness
to further agonist challenge.
11 This process, known as receptor
desensitization, has been shown to protect cells from the
adverse effects of over-stimulation or inappropriate signalling.
Phosphorylation of key serine and/or threonine residues within
the third intracellular loop and/or C-terminal tail of the G
protein-coupled receptor is thought to be the primary event initi-
ating desensitization and is often mediated by one or more
members of a family of seven serine/threonine kinases, the G
protein-coupled receptor kinases (GRKs).
11 Phosphorylation by
GRKs enhances receptor afﬁnity for the non-visual arrestins 2
and 3, which can sterically suppress further interaction between
receptor and G proteins.
12
Although previous studies have shown that recombinantly
expressed ETARs are phosphorylated and desensitized in a
GRK-dependent manner in model cells, such as HEK293 cells,
13
little evidence is currently available to indicate which, if any,
GRKs regulate endogenous ETAR signalling in vascular smooth
muscle. This is an important issue as recombinant receptors are
often regulated very differently to those expressed endogenously.
Indeed, a growing number of studies are revealing that precise deﬁ-
nition of the GRKs involved in receptor regulation can only be
truly deﬁned in a system endogenously expressing the receptor
of interest and through manipulation of endogenous GRK popu-
lations.
11,14–16 Here, we have combined confocal imaging tech-
niques and speciﬁc inhibition of endogenous GRK isoenzymic
activities to examine the interaction between GRKs and the
native ETAR population in isolated, cultured mesenteric smooth




2.1 Isolation and culture of mesenteric
arterial smooth muscle cells
Adult male Wistar rats were sacriﬁced by stunning and cervical dislo-
cation, a method approved under the UK Animals (Scientiﬁc Pro-
cedures) Act 1986. Smooth muscle cells were isolated from small
branches of mesenteric artery by enzymatic dissociation as previously
described.
17 Smooth muscle cells were separated by gentle trituration in
231 medium (Cascade Biologics, Nottingham, UK), supplemented with
smooth muscle growth supplement, 100 IU
21 penicillin, 100 mg/mL
streptomycin, and 2.5 mg/mL amphotercin B. Cells plated onto cover-
slips were maintained at 378C, 5% CO2 in humidiﬁed conditions.
MSMCs were characterized by immunocytochemistry and immunoblot-
ting for the presence of smooth muscle-speciﬁc a-actin and calponin
(data not shown). The investigation conforms to Guide for Care and
Use of Laboratory Animals US (NIH Publication No. 85-23, revised
1996).
2.2 Immunocytochemistry
MSMCs were cultured for 72 h before ﬁxation and permeabilization in
100% methanol (10 min at 2208C). GRK expression was identiﬁed
through addition of speciﬁc anti-rabbit polyclonal antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) against GRK2, GRK3,
GRK5, and GRK6. Protein expression was visualized with the addition
of ﬂuorescein isothiocyanate-conjugated secondary antibodies, before
viewing on an Olympus FV500 laser scanning confocal IX70 inverted
microscope.
2.3 Small interfering RNA knockdown of
endogenous GRK2 levels and western
blotting
Expression of GRKs and dominant-negative GRKs (see below) was
determined using standard immunoblotting protocols as described
previously
14 using speciﬁc anti-rabbit polyclonal antibodies against
GRK2, GRK3, GRK5, and GRK6. MSMCs (1   10
6) were
transfected with 10 or 100 nM negative-control or anti-GRK2
(50-GCAGGUACCUCCAGAUCUCtt-30) (Applied Biosystems, UK)
small interfering (si)RNAs. Cells were lysed after 48 h and GRK
expression assessed by immunoblotting (see above). GRK expression
was quantiﬁed using the GeneGnome image analysis system
(Syngene, Cambridge, UK).
2.4 Manipulating cellular GRK activity
GRK2/3 constructs were mutated in both the N-terminal RGS-like
domain (D110A) (to prevent binding to Gaq/11 proteins
11) and the
catalytic-domain (K220R) to allow potential receptor/GRK





structs, normal PLC signalling was unaffected. In contrast, expression
of
K220RGRK2 or
K220RGRK3 markedly attenuated PLC signalling (data
not shown), most likely through the previously reported
phosphorylation-independent inhibition of Gaq/11 transduction
through an interaction with the GRK2/3 RGS-homology (RH) domain.
19





K215RGRK6 (0.5 mg), negative-control plasmid (pcDNA3), or through
addition of anti-GRK2, or negative-control siRNAs (10 nM). Cells
were transfected using LipofectAMINE2000 (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions.
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MSMCs were transfected (24–48 h after isolation) with the pleckstrin-
homology domain of PLCd1 tagged with enhanced green ﬂuorescent
protein (eGFP-PH, 0.5 mg), a previously extensively characterized IP3
biosensor.
18 Cells were maintained at 378C by a Peltier unit and con-
tinually perfused with a modiﬁed Krebs-Henseleit buffer (in mM: NaCl
134, KCl 6, MgCl2 1, glucose 10, HEPES 10, CaCl2 1.3, pH 7.4). Real-
time images were taken using an Olympus FV500 laser scanning con-
focal IX70 inverted microscope (oil immersion objective  60). Cells
transfected with eGFP-PH and loaded with Fura-Red were excited
(Ex) at 488 nm and eGFP-PH and Fura-Red emissions (Em) were col-
lected at 505–560 and .660 nm, respectively. ET-1 (50 nM) was
applied via the perfusion line as indicated. Changes in cytosolic
eGFP-PH ﬂuorescence are represented as the ﬂuorescence emission
(F)/initial basal ﬂuorescence (F0)( F/F0) and increases in intracellular
Ca
2þ ([Ca
2þ]i) are reported by Fura-Red as decreases in F/F0 ﬂuor-
escence. Additional Ca
2þ experiments in the absence of eGFP-PH
were conducted using Fluo-4-AM (3 mM, 60 min) and imaged as for
eGFP above.
To assess GRK2 effects on ET-1-stimulated DAG/PKC signalling,
MSMCs were transfected with eGFP-PKCa
20 or eGFP-PKC1
20
(0.5 mg), and anti-GRK2 siRNA as above. After 48 h, cells were
loaded with Fura-Red (3 mM) for 50 min before commencing imaging
experiments.
2.6 Data and statistical analysis
Data presented are from cells obtained from at least three separate
preparations and are expressed as means+SEM. Data were analysed
using one-way ANOVA as indicated, with appropriate post hoc testing
(GraphPad Prism, San Diego, CA, USA).
3. Results
3.1 ETAR desensitization and
re-sensitization
ET-1 activation of PLC signalling was assessed in MSMCs trans-
fected with the eGFP-PH biosensor and loaded with the Ca
2þ-
sensitive dye Fura-Red to allow simultaneous measurement of
changes in IP3 and [Ca
2þ]i.
18 Continual ET-1 (50 nM) challenge
produced transient [Ca
2þ]i increases, which rapidly returned to
basal within 100 s (Figure 1A). Short applications (30 s) of ET-1
stimulated transient concentration-dependent translocations of
eGFP-PH from the plasma membrane to the cytoplasm and
increases in [Ca
2þ]i, with maximal effects at concentrations of
ET-1 of  50 nM (data not shown). The ETAR antagonist BQ123
(1 mM) blocked ET-1-stimulated signals, suggesting that in our
MSMC preparations ETARs are primarily responsible for PLC sig-
nalling (data not shown). To assess the time courses of ETAR
desensitization and re-sensitization MSMCs were challenged with
a short desensitizing pulse of ET-1 (50 nM, for 30 s, termed R1)
followed by a wash period (of 10, 20, 30, or 60 min) and a
second ET-1 challenge (50 nM, 30 s, termed R2). Initial ET-1 chal-
lenge (R1) increased eGFP-PH translocation and [Ca
2þ]i with
responses returning to basal within 5 min of agonist washout
(Figure 1B). A second ET-1 challenge applied 10 min after R1
caused less translocation of eGFP-PH and a reduced [Ca
2þ]i
response (Figure 1B). The reduction in the R2/R1 ratio can be inter-
preted as an indicator of ETAR desensitization.
14,19 Increasing the
washout period provided evidence of a slow and incomplete
re-sensitization, with R2 for the IP3 response still 70% less than
R1 after 60 min (Figure 1C, D).
3.2 GRK expression in MSMCs
Immnuoblotting data showed that GRKs 2, 5, 6 are expressed in rat
MSMCs, however, in agreement with the previous ﬁndings
16 we
were unable to detect GRK3 expression (see Supplementary
material online, Figure S1). Immunocytochemical evidence high-
lights an anticipated cytoplasmic distribution of GRK2 (Figure 6A),
whereas GRK5 expression appears to be primarily nuclear
(Figure 6B and C).
3.3 Effects of inhibiting endogenous GRK
activities on ETAR signalling
To determine which endogenous GRKs modulate ETAR signalling,
we inhibited individual GRK isoenzymes by over-expressing cataly-
tically inactive, dominant-negative GRK mutants. This approach
has been successfully used in a number of studies to bring about
highly selective GRK isoenzymic inhibition.
14,15 MSMCs were






21 MSMCs transfected with dominant-negative GRKs
were subjected to the standard desensitization protocol (R1/R2)
with 10 min washout between ET-1 additions. Control exper-
iments, co-transfecting monomeric red ﬂuorescent protein and
eGFP-tagged dominant-negative GRKs indicated .90%
co-transfection of cells (data not shown). In MSMCs transfected
with pcDNA3 (Figure 2A, B, G),
D110A,K220RGRK3 (Figure 2D, G),
K215RGRK5 (Figure 2E, G), or
K215RGRK6 (Figure 2F, G), the
reduction in R2 compared with R1 was consistently  80% for
eGFP-PH and  60% for [Ca
2þ]i signals, indicating similar
reductions in ETAR responsiveness to those observed in untrans-
fected cells. However, in the presence of
D110A,K220RGRK2, the
R2 IP3 response was decreased by 40% relative to R1, whereas
the reduction in R2 for the ET-1-stimulated Ca
2þ signal was
almost completely ablated (Figure 2A, C, G). These data indicate
that inhibition of endogenous GRK2 activity results in a highly sig-
niﬁcant attenuation of ET-1-induced ETAR desensitization.
To conﬁrm and extend our ﬁndings, MSMCs were transfected
with siRNAs designed to target GRK2. Optimal depletion of
endogenous GRK2 was achieved 48 h after siRNA transfection at
concentrations of siRNA of  10 nM (Figure 3A, B). This effect
was shown to be GRK2-speciﬁc as the anti-GRK2-siRNA did not
affect GRK6 expression (Figure 3A, B). A negative-control siRNA
had no effect on either GRK2 or GRK6 expression (Figure 3B).
In addition, we co-transfected MSMCs with eGFP (0.5 mg) and
either negative-control or anti-GRK2 siRNAs (10 or 100 nM)
and 48 h later GRK2 expression was determined immunocyto-
chemically. Our previous work indicates that co-transfection
rates are .90%; therefore, we have assumed that all
eGFP-expressing cells were also transfected with siRNA con-
structs. When compared with non-eGFP-expressing cells, the
presence of eGFP and negative-control siRNA did not affect
GRK2 expression (data not shown), however, transfection with
anti-GRK2 siRNA caused a marked reduction (75%) in GRK2
G.E. Morris et al. 426immunoreactivity (Figure 3C, D), whereas GRK5 and 6 expression
was unaffected (Figure 3D).
To examine the effect of siRNA-mediated GRK2 knockdown on
ETAR desensitization, MSMCs were co-transfected with eGFP-PH
(0.5 mg) and negative-control (10 nM) or anti-GRK2 (10 nM)
siRNAs and subjected to the standard R1/R2 desensitization pro-
tocol. In the presence of negative-control siRNA, R2 responses
were decreased by  80% for eGFP-PH and by  60% for
[Ca
2þ]i signals compared with R1, consistent with the degree of
receptor desensitization observed in untransfected cells
(Figure 4A, B, D). In contrast, in cells transfected with anti-GRK2
siRNA, R2 and R1 responses were similar to those previously
seen in
D110A,K220RGRK2-transfected MSMCs, with a 50% decrease
in eGFP-PH and 30% decrease in Ca
2þ signals (Figure 4A, C, D).
To assess whether quantitatively similar effects of manipulating
cellular GRK2 are seen with respect to the DAG/PKC arm of the
ETAR signalling pathway, we have assessed ET-1-stimulated translo-
cation of the Ca
2þ and DAG-sensitive PKCa and DAG-sensitive
PKC1 isoenzymes. Applying the standard desensitization protocol
to eGFP-PKCa-( Figure 5A, C) or eGFP-PKC1 (Figure 5B, C)-
transfected MSMCs showed that a signiﬁcantly greater recovery
with respect to PKC recruitment responses was also observed
when cellular GRK2 levels were selectively diminished.
3.4 ET-1-stimulated recruitment of
endogenous GRKs
To investigate further GRK2-mediated regulation of ETAR signal-
ling, we examined the redistribution of this GRK isoenzyme follow-
ing ET-1 addition. The MSMCs were treated with ET-1 (50 nM) for
3 min, after which cells were ﬁxed and processed to allow
immunocytochemical detection of GRKs. Confocal images show
GRK2 recruitment to the plasma membrane following ET-1
exposure (Figure 6A). The predominantly nuclear localization of
GRK5 was unaltered following ET-1 challenge (Figure 6B),
whereas addition of the Ca
2þ-ionophore ionomycin promoted
Figure 1 Kinetics of ETAR desensitization and re-sensitization. (A) Representative trace showing desensitization of ETAR [Ca
2þ]i signals fol-
lowing ET-1 challenge (50 nM, 3 min) in Fluo4-loaded MSMCs. Data are representative of 16 cells from three or more separate animals. MSMCs
were transfected with 0.5 mg eGFP-PH and loaded with Fura-Red and subjected to the standard R1/R2 desensitization protocol: cells were
stimulated with ET-1 (50 nM, 30 sec) (R1), followed by a variable period of 10, 20, or 30 min before further ET-1 (50 nM, 30 s) exposure
(R2). Representative traces from single cells with either a 10 min (B) or 30 min (C) wash period are shown. ETAR desensitization was deter-
mined as the relative change in R2 response compared with R1 for both eGFP-PH (solid traces) and Fura-Red (broken traces). (D) Cumulative
data shown as means+SEM from 14–15 cells from three or more different animals.





K215RGRK6 (0.5 mg). Cells were loaded with Fura-Red and subjected
to the standard R1/R2 desensitization protocol (see Methods). Representative images showing both IP3 and Ca
2þ changes in MSMCs expressing
pcDNA3 (control) or
D110A,K220RGRK2 at both the R1 and R2 stimulation points are shown in (A). Representative traces are from cells trans-




K215RGRK6 (F). ETAR desensitization was determined
as the relative change in R2 response compared with R1 for both eGFP-PH (black traces) and Fura-Red (broken traces). Cumulative data (G) are
expressed as means+SEM for the percentage change in R2 relative to R1; n ¼ 7–17 cells for each time-point, from at least eight separate
experiments from three or more different animals. Statistical signiﬁcance is indicated as **P , 0.01 vs. pcDNA3 (one-way ANOVA and Dun-
nett’s post hoc test).
G.E. Morris et al. 428GRK5 translocation to the cytoplasm (Figure 6C). We were unable
to detect recruitment of GRK3 (data not shown), and due to its
‘constitutive’ plasma membrane localization GRK6
11 was not
studied here.
3.5 Does protein kinase C have a role
in ETAR desensitization
ETAR activation can recruit PKC isoenzymes to the plasma mem-
brane
20 raising the possibility that PKCs may also be involved in
ETAR regulation. To assess whether PKC plays a role in ETAR
desensitization, we used two complementary approaches: (i) pre-
incubation of MSMCs with staurosporine (1 mM) or dimethyl
sulphoxide (vehicle control) for 10 min prior to and throughout
the standard R1/R2 desensitization protocol and (ii) down-
regulation of PKC isoenzymes by a 24 h pre-treatment with
phorbol 12,13-dibutyrate (PDBu, 1 mM). Neither acute treatment
with staurosporine (see Supplementary material online, Figure
S2C, E) nor chronic phorbol ester treatment (see Supplementary
material online, Figure S2E) had any effect on ET-1-induced ETAR
desensitization. In addition, the magnitude of effect on ETAR
desensitization caused by the siRNA GRK2 knockdown strategy
was unaltered in MSMCs additionally treated with either
staurosporine or chronic PDBu (see Supplementary material
online, Figure S2D, E).
4. Discussion
ET-1, a potent vasoconstrictor important in the regulation of vas-
cular tone, has also been reported to promote vascular hypertro-
phy and hyperplasia.
1,3,4 In vascular smooth muscle, ETAR has been
shown to be the dominant receptor subtype mediating ET-1
smooth muscle contraction.
8 In agreement, we ﬁnd that ET-1
acts through the ETAR to activate Gaq/11/PLC signalling and to
elevate [Ca
2þ]i in our MSMC preparations
2,20 (ultimately to modu-
late other pathways, including a number of K
þ conductances
9 and
cause contraction). Despite the clear potential pathophysiological
importance of ETAR, relatively little is currently known regarding
the regulation of this receptor subtype in native vascular tissue.
To address this, we have used simultaneous confocal imaging of
IP3 (using eGFP-PH), [Ca
2þ]i (using the Ca
2þ-sensitive dye
Fura-Red), and DAG/PKC (using eGFP-PKCs) to investigate
ETAR regulation by ET-1 in smooth muscle cells within days of iso-
lation from resistance arteries. MSMC culture conditions were
chosen to enable us to examine ETAR regulation in cells maintain-
ing as far as possible an in vivo phenotype. High levels of a-actin and
Figure 3 Anti-GRK2 siRNA causes endogenous GRK2 protein depletion. MSMCs were transfected with control or anti-GRK2 siRNAs (10 or
100 nM) using Amaxa nucleofection. After 48 h, cells were lysed and 40 mg of protein loaded for SDS–PAGE separation and immunoblotting.
(A) Representative western blots of GRK2 and GRK6 levels are shown: untreated cells (lane 1), cells treated with 10 or 100 nM of anti-GRK2
siRNA (lanes 2 and 3, respectively), 10 or 100 nM negative-control siRNA (lanes 4 and 5, respectively). (B) Cumulative densitometric data show
means+SEM from three animals. (C) Representative images showing depletion of endogenous GRK2 in 4-day-old isolated MSMCs, 48 h after
transfection with the same GRK2 siRNA validated in (A and B). On the left are eGFP-transfected cells and the right GRK2 immunoreactivity. (D)
Cumulative immunocytochemical data showing that GRK2 siRNA treatment signiﬁcantly decreased GRK2, but not GRK5 or GRK6 expression
in MSMCs. Data are means+SEM for 20–65 cells for each treatment from three separate animals. Statistical signiﬁcance is indicated as
**P , 0.01 vs. untreated cells (one-way ANOVA and Dunnett’s post hoc test).
GRK2 regulates endothelin signalling 429calponin expression, combined with visual evidence of smooth
muscle cell contractions elicited by ET-1 (and other contractile
agonists) indicated the maintenance of a contractile phenotype in
these cultures.
In agreement with the previous reports, for example in HEK293
cells,
22 the initial increase in [Ca
2þ]i stimulated by ET-1 in MSMCs
rapidly declined towards basal, even in the continued presence of
agonist. Brief (30 s) exposure to ET-1 was sufﬁcient to cause
extensive and prolonged loss of ETAR responsiveness to sub-
sequent ET-1 re-challenge with respect to both IP3 and Ca
2þ
signals. As expected, Ca
2þ signals showed more rapid recovery
than IP3 signals reﬂecting the greater ampliﬁcation of the former
signal in the ET-1-stimulated ETAR-PLC signalling pathway. Pre-
vious studies in arterial tissue have tended to use prolonged
(.60 min) ET-1 exposures leading to marked reductions in arterial
contractions on ET-1 re-challenge, indicating profound ETAR
desensitization
23 and most probably ETAR down-regulation.
24
Data from studies in recombinant cell systems suggest that
GRKs are able to regulate ETAR signalling.
13 Indeed, when
expressed in HEK293 cells, ETAR rapidly desensitized, and
Figure 4 Depletion of endogenous GRK2 inhibits ETAR desensitization. MSMCs were co-transfected with 0.5 mg eGFP-PH and either
negative-control or anti-GRK2 (10 nM) siRNAs. Cells were loaded with Fura-Red and subjected to the standard R1/R2 desensitization protocol
(see Methods). (A) Representative images of changes in IP3 and Ca
2þ in MSMCs expressing either control siRNA or anti-GRK2 siRNA at both
the R1 and R2 stimulation points are shown. Representative traces from single cells transfected with control siRNA (B) or anti-GRK2 siRNA
(C). ETAR desensitization was determined as the relative change in R2 response compared with R1 for both eGFP-PH (black traces) and
Fura-Red (broken traces). Cumulative data (D) show means+SEM from 7–9 cells from four or more animals. Statistical signiﬁcance is indicated
as **P , 0.01; ***P , 0.001 (one-way ANOVA, unpaired t-test).
G.E. Morris et al. 430phosphorylation of the receptor was enhanced by recombinant
over-expression of GRKs 2, 5, or 6.
13 In addition, over-expression
of recombinant GRK2 and GRK3 increased ETAR phosphorylation
in CHO cells.
25 Together these and other studies suggest that
GRKs are able to cause ETAR phosphorylation, however, such
studies are not necessarily predictive of how/if the receptor will
be regulated by speciﬁc GRK isoenzymes in native ETAR
expression systems. Therefore, a key objective here was to delin-
eate for the ﬁrst time the role that endogenous GRK isoenzymes
play in ETAR regulation in resistance artery smooth muscle. Owing
to the lack of effective and speciﬁc pharmacological GRK inhibitors,
we applied previously validated molecular approaches to disrupt or
decrease activity of speciﬁc endogenous GRK isoenzymes. Initially,
we used dominant-negative (kinase-dead) GRK mutants to disrupt
ETAR/GRK isoenzyme-speciﬁc interactions in an attempt to
attenuate or prevent the reduction in ETAR responsiveness
observed on re-addition of ET-1. The
D110A,K220RGRK2 construct,
Figure 5 GRK2 depletion decreases ET1-induced desensitiza-
tion of ETA receptor-stimulated PKC recruitment. MSMCs
were co-transfected with 0.5 mg of either eGFP-PKCa or
eGFP-PKC1 and negative-control or anti-GRK2 (10 nM)
siRNAs. Representative traces showing eGFP-PKC1 (A)o r
eGFP-PKCa (B) translocations in MSMCs subjected to the stan-
dard R1/R2 desensitization protocol (see Methods) in the pres-
ence of negative-control (broken traces) or GRK2 siRNA
(black traces). Cumulative data (C) are shown as means+SEM
from 8–20 cells from three to four animals. Statistical signiﬁcance
is indicated as *P , 0.05; **P , 0.01 (one-way ANOVA, Dun-
nett’s post hoc test).
Figure 6 ET-1 stimulates recruitment of endogenous GRK2,
but not GRK5 to the plasma membrane. MSMCs were challenged
with ET-1 (50 nM) for 3 min, before ﬁxation and processing for
immunocytochemical detection of GRKs 2 and 5 (see
Methods). Representative confocal images show the distribution
of GRK2 and GRK5 in MSMCs. Left-hand panels are images of
untreated cells, whereas the right-hand panels show: (A) GRK2
recruitment to the plasma membrane after ET-1 challenge (indi-
cated by arrows); (B) Lack of movement of GRK5 after ET-1 chal-
lenge; (C) Redistribution of GRK5 from the nucleus to the
cytoplasm after ionomycin (2 mM, 15 min) treatment. Data are
representative of experiments from cells isolated from three sep-
arate animals.
GRK2 regulates endothelin signalling 431which is mutated to prevent both kinase activity and Gaq/
11-binding,





mutants had no effect on the extent or time course of recovery
of ETAR responsiveness to ET-1.
A potential criticism of the dominant-negative GRK over-
expression approach is the possibility of ‘off-target’ effects or lack
of sufﬁcient speciﬁcity towards the GRK isoenzyme being targeted.
This clearly was not the case here given the marked contrast
between effects of the GRK2 and 3 constructs, nevertheless, to
provide a complementary experimental approach we used speciﬁc
siRNAs to deplete (by  75%) endogenous GRKs in MSMCs. In
agreement with the
D110A,K220RGRK2 experiments, siRNA-induced
depletion of GRK2 also markedly attenuated the ET-1-induced
ETAR desensitization with respect to IP3,C a
2þ,a n dD A G / P K C
signal readouts. Furthermore, redistribution of endogenous GRK2
from the cytoplasm to the membrane could be detected after a
brief ET-1 stimulation, most likely indicating recruitment to
agonist-occupied ETARs. Interestingly, despite previous reports of
the plasma membrane association of GRK5, this isoenzyme is predo-
minantly located within the nuclei of MSMCs. Nuclear accumulation
of GRK5 has been reported previously in cardiomyocytes,
26 pre-
sumably as a consequence of its nuclear localization sequence.
27
Our study also represents a ﬁrst report of the nuclear GRK5 local-
ization in MSMCs, although the signiﬁcance of this ﬁnding for GPCR
signalling and vascular physiology remains to be established.
Collectively, these data indicate that GRK2 is the key endogen-
ous GRK subtype initiating ETAR desensitization in MSMCs, with
either GRK2 knockdown or disruption of the normal GRK2-
ETAR interactions causing an 50% attenuation of ETAR desensi-
tization. This partial blockade may arise, because the experimental
strategy is incompletely effective, or may indicate that other, so far
undeﬁned mechanisms are involved in regulating ETAR responsive-
ness. In MSMCs, ETAR activation is known to recruit several PKC
isoenzymes
9,20 and PKC activation is known to phosphorylate
ETAR, at least in a HEK293 cell background,
13 suggesting a poten-
tial role for this protein kinase family in ETAR desensitization. In
addition, PKCs are also known to phosphorylate GRK2 enhancing
its membrane recruitment
28 and ability to desensitize GPCRs.
29
Unfortunately, most of the available PKC inhibitors are ﬂuorescent
molecules precluding their use with the translocating, ﬂuorescent
biosensors. Consequently, we used the complementary
approaches of inhibiting PKC activity with either the broad-
speciﬁcity PKC inhibitor staurosporine, or down-regulating con-
ventional and novel PKC isoenzymes through chronic treatment
of MSMCs with the phorbol ester, PDBu. Neither manipulation
of MSMCs suggested that PKCs play a role in the ETAR desensiti-
zation process nor alter the ability of GRK2 to exert its effect on
the ETAR. Nevertheless, it remains a possibility that PKC-mediated
ETAR phosphorylation may have as yet undeﬁned roles in directing
the signalling outputs of this receptor subtype (e.g. ET-1-mediated
inhibition of K
þ channels to alter vasoconstrictor responses
9,17).
Nonetheless, since GRK2 inhibition appears only partially to
prevent ETAR desensitization, it is possible that other mechanisms
are involved, perhaps involving more distal regulatory processes
such as b-arrestin binding,
25 receptor internalization and/or recep-
tor down-regulation.
24
Accumulating evidence indicates that GRKs play an important
role in the pathogenesis of vascular disease. In experimental
systems, adenovirus-mediated over-expression of GRK2 in cul-
tured rabbit aortic smooth muscle cells attenuated ET-1-induced
proliferation,
30 whereas a two- to three-fold over-expression of
GRK2 in vascular smooth muscle signiﬁcantly reduced functional
(increases in mean arterial pressure) responses to angiotensin II
in mice.
31 These ﬁndings suggest a protective role for GRK2
expression, presumably by enhancing the desensitization of these
pro-hypertensive signals. However, in apparent contradiction to
these ﬁndings, GRK2 expression has been reported to be
enhanced in both hypertensive patients
32 and rat models of hyper-
tension. A possible explanation for this discrepancy is that over-
expression of GRK2 not only attenuates vasoconstrictor (e.g.
angiotensin II) signalling, but also vasodilator signalling. Speciﬁcally,
signalling through the b2-adrenoceptor is substantially reduced in
vascular smooth muscle over-expressing GRK2.
31 In addition,
since GRK2 is able to suppress Gaq-signalling through its N-
terminal RGS-like domain,
11 it is conceivable that elevated GRK2
expression is initially an adaptive response to over-stimulation of
Gaq-signalling pathways, preventing inappropriate vasoconstriction
and resultant hypertension.
33 It is therefore clear that GRK2 is
linked to hypertensive adaptations, but its exact role in the devel-
opment of hypertension merits further investigation. In summary,
here we have provided important new evidence highlighting the
role played by GRK2 in regulating ET-1/ETAR/Gaq-mediated vaso-
constriction and suggest that this GRK isoenzyme might protect
against ET-1-induced vascular dysfunction.
1,3–6,34
Supplementary material
Supplementary Material is available at Cardiovascular Research
online.
Acknowledgements
We thank Tobias Meyer (Stanford University, USA) for generously
providing the eGFP-PH biosensor, and Stephen Ferguson (Univer-
sity of Western Ontario, Canada) for the gift of eGFP-tagged PKC
isoenzymes.
Conﬂict of interest: none declared.
Funding
This work was generously supported by the British Heart Foundation
[PG06/161/22136 and RG06/008/22062]. Funding to pay the Open
Access publication charges for this article was provided by the
British Heart Foundation.
References
1. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart
2003;89:1104–1109.
2. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol
Rev 2001;81:999–1030.
3. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat
vascular smooth muscle cells. Atherosclerosis 1989;78:225–228.
4. Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies.
Can J Physiol Pharmacol 2003;81:578–587.
5. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy.
Hypertension 1995;25:1135–1143.
G.E. Morris et al. 4326. d’Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic
ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997;
29:435–441.
7. Schneider MP, Hilgers KF, Klingbeil AU, John S, Veelken R, Schmieder RE. Plasma
endothelin is increased in early essential hypertension. Am J Hypertens 2000;13:
579–585.
8. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to
endothelin peptides in human blood vessels in vitro. Br J Pharmacol 1995;115:
191–197.
9. Rainbow RD, Hardy ME, Standen NB, Davies NW. Glucose reduces endothelin
inhibition of voltage-gated potassium channels in rat arterial smooth muscle
cells. J Physiol 2006;575:833–844.
10. Moreau P, Schiffrin EL. Role of endothelins in animal models of hypertension:
focus on cardiovascular protection. Can J Physiol Pharmacol 2003;81:511–521.
11. Willets JM, Challiss RAJ, Nahorski SR. Non-visual GRKs: are we seeing the whole
picture? Trends Pharmacol Sci 2003;24:626–633.
12. Luttrell LM, Lefkowitz RJ. The role of b-arrestins in the termination and transduc-
tion of G-protein-coupled receptor signals. J Cell Sci 2002;115:455–465.
13. Freedman NJ, Ament AS, Oppermann M, Stoffel RH, Exum ST, Lefkowitz RJ.
Phosphorylation and desensitization of human endothelin A and B receptors. Evi-
dence for G protein-coupled receptor kinase speciﬁcity. J Biol Chem 1997;272:
17734–17743.
14. Willets JM, Taylor AH, Shaw H, Konje JC, Challiss RAJ. Selective regulation of H1
histamine receptor signaling by G protein-coupled receptor kinase 2 in uterine
smooth muscle cells. Mol Endocrinol 2008;22:1893–1907.
15. Willets JM, Challiss RAJ, Nahorski SR. Endogenous G protein-coupled receptor
kinase 6 Regulates M3 muscarinic acetylcholine receptor phosphorylation and
desensitization in human SH-SY5Y neuroblastoma cells. J Biol Chem 2002;277:
15523–15529.
16. Cohn HI, Harris DM, Pesant S, Pfeiffer M, Zhou RH, Koch WJ et al. Inhibition of
vascular smooth muscle G protein-coupled receptor kinase 2 enhances a1D-
adrenergic receptor constriction. Am J Physiol 2008;295:H1695–H1704.
17. Hayabuchi Y, Dart C, Standen NB. Evidence for involvement of A-kinase anchor-
ing protein in activation of rat arterial KATP channels by protein kinase A. J Physiol
2001;536:421–427.
18. Nelson CP, Nahorski SR, Challiss RAJ. Temporal proﬁling of changes in phospha-
tidylinositol 4,5-bisphosphate, inositol 1,4,5-trisphosphate and diacylglycerol
allows comprehensive analysis of phospholipase C-initiated signalling in single
neurons. J Neurochem 2008;107:602–615.
19. Willets JM, Nahorski SR, Challiss RAJ. Roles of phosphorylation-dependent and
-independent mechanisms in the regulation of M1 muscarinic acetylcholine recep-
tors by G protein-coupled receptor kinase 2 in hippocampal neurons. J Biol Chem
2005;280:18950–18958.
20. Nelson CP, Willets JM, Davies NW, Challiss RAJ, Standen NB. Visualizing the
temporal effects of vasoconstrictors on PKC translocation and Ca
2þ signaling
in single resistance arterial smooth muscle cells. Am J Physiol 2008;295:
C1590–C1601.
21. Willets JM, Nash MS, Challiss RAJ, Nahorski SR. Imaging of muscarinic acetyl-
choline receptor signaling in hippocampal neurons: evidence for phosphorylation-
dependent and -independent regulation by G-protein-coupled receptor kinases.
J Neurosci 2004;24:4157–4162.
22. Dai X, Galligan JJ. Differential trafﬁcking and desensitization of human ETA and
ETB receptors expressed in HEK 293 cells. Exp Biol Med 2006;231:746–751.
23. Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E et al. Effects of
human urotensin II in isolated vessels of various species; comparison with
other vasoactive agents. Naunyn Schmiedeberg’s Arch Pharmacol 2002;365:
141–149.
24. Rao VR, Krishnamoorthy RR, Yorio T. Endothelin-1, endothelin A and B receptor
expression and their pharmacological properties in GFAP-negative human lamina
cribrosa cells. Exp Eye Res 2007;84:1115–1124.
25. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H. Regu-
lation and intracellular trafﬁcking pathways of the endothelin receptors. J Biol
Chem 2000;275:17596–17604.
26. Yi XP, Zhou J, Baker J, Wang X, Gerdes AM, Li F. Myocardial expression and
redistribution of GRKs in hypertensive hypertrophy and failure. Anat Rec A
Discov Mol Cell Evol Biol 2005;282:13–23.
27. Johnson LR, Scott MG, Pitcher JA. G protein-coupled receptor kinase 5 contains a
DNA-binding nuclear localization sequence. Mol Cell Biol 2004;24:10169–10179.
28. Mundell SJ, Pula G, McIlhinney RA, Roberts PJ, Kelly E. Desensitization and intern-
alization of metabotropic glutamate receptor 1a following activation of heter-
ologous Gq/11-coupled receptors. Biochemistry 2004;43:7541–7551.
29. Chuang TT, LeVine H, De Blasi A. Phosphorylation and activation of b-adrenergic
receptor kinase by protein kinase C. J Biol Chem 1995;270:18660–18665.
30. Peppel K, Jacobson A, Huang X, Murray JP, Oppermann M, Freedman NJ. Over-
expression of G protein-coupled receptor kinase-2 in smooth muscle cells
attenuates mitogenic signaling via G protein-coupled and platelet-derived
growth factor receptors. Circulation 2000;102:793–799.
31. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ. Vascular-targeted
overexpression of G protein-coupled receptor kinase-2 in transgenic mice
attenuates b-adrenergic receptor signaling and increases resting blood pressure.
Mol Pharmacol 2002;61:749–758.
32. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase
activity is increased in hypertension. J Clin Invest 1997;99:2087–2093.
33. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD.
G-Protein-coupled receptor kinase activity in hypertension: increased vascular
and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension
2000;35:38–42.
34. Touyz RM, Turgeon A, Schiffrin EL. Endothelin-A-receptor blockade improves
renal function and doubles the lifespan of stroke-prone spontaneously hyperten-
sive rats. J Cardiovasc Pharmacol 2000;36(Suppl. 1):S300–S304.
GRK2 regulates endothelin signalling 433